Healthleap has raised $38 million to expand an AI platform that reads hospital records and flags patients who may need closer clinical review. TechCrunch reported on October 7 that the financing combines an $8 million seed round co-led by Sequoia Capital and First Round Capital with a $30 million Series A led by Hummingbird Ventures. The company did not disclose its valuation.

Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, Healthleap began with a clinical nutrition product for dietitians before shifting toward a broader hospital-screening platform. The company now focuses on conditions that may not be recognized early enough, including malnutrition and delirium. It has also developed programs for aspiration pneumonia, pressure ulcers and the risk of readmission for congestive heart failure, although the chief executive told TechCrunch those programs are still undergoing further clinical validation.

Structured clinical data and written notes flow into a transparent risk filter.
The platform uses language models and risk models together, but it does not make a diagnosis.

The system connects to a hospital's electronic health record and combines structured information, such as laboratory results, vital signs and patient weights, with details extracted from clinicians' written notes. Language models look for concepts such as recent weight loss or difficulty swallowing, while the platform's risk models use those findings to surface cases for care teams. Healthleap says the software does not diagnose a condition; it highlights information that warrants additional review.

According to the company, the platform analyzes adult inpatient records overnight and places a risk score into the care team's existing workflow the following morning. A supporting dashboard shows patient trends and other context. Healthleap's chief executive told TechCrunch that the technology is deployed in more than 50 hospitals, up from three hospital partners a year earlier, with customers including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare.

A digital risk marker reaches a review station before a human-controlled decision gate.
Healthleap plans to expand to more conditions, making clinical validation and human review central to its growth.

Healthleap also reported rapid business growth and substantial financial results, but those figures were supplied by the company rather than independently established in the article. Its chief executive said revenue increased more than tenfold over the past year and that customers achieved at least five times their contract price in validated financial returns. At the Hospital of the University of Pennsylvania, Healthleap attributed $23.8 million in annualized impact to its malnutrition program, including $6.3 million in additional reimbursement and $17.5 million tied to shorter stays.

The startup plans to use the new funding for engineering, product development, sales and customer success while adding support for more conditions. Its long-term target is to cover more than 40 major health conditions and expand beyond hospitals into outpatient and home care. The central test will be whether broader deployment preserves clinical reliability: a tool that prioritizes cases could help care teams focus attention, but its value depends on validating the underlying risk models and keeping human review at the point where a flag becomes a medical decision.